The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn’s Disease

(2020) Jacob E. Ollech et al.   Clinical Gastroenterology and Hepatology

DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry

(2020) V Biemans drs et al.   Journal of Crohns & Colitis

Should We Divide Crohn’s Disease Into Ileum-Dominant and Isolated Colonic Diseases?

(2019) Parambir S. Dulai et al.   Clinical Gastroenterology and Hepatology

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

(2019) Aurelien Amiot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

(2019) Peter Hoffmann et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease

(2018) S. Singh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

(2018) P. Wils et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients

(2018) Cristiano Pagnini et al.   Gastroenterology Research and Practice

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detections of complications

(2018) Christian Maaser et al.   Journal of Crohns & Colitis

Ustekinumab Is Effective for the Treatment of Crohn’s Disease of the Pouch in a Multicenter Cohort

(2018) Kimberly N Weaver et al.   INFLAMMATORY BOWEL DISEASES

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

(2017) Siew C Ng et al.   LANCET

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study

(2017) Subra Kugathasan et al.   LANCET

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Dynamics of the human gut microbiome in inflammatory bowel disease

(2017) Jonas Halfvarson et al.   Nature Microbiology

Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014

(2016) J. Kirchgesner et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease

(2016) Floris Imhann et al.   GUT

Molecular classification of Crohn's disease reveals two clinically relevant subtypes

(2016) Matthew Weiser et al.   GUT

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

(2016) Isabelle Cleynen et al.   LANCET

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis

(2016) Peter C. Austin   STATISTICS IN MEDICINE

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals

(2009) Stanley Xu et al.   VALUE IN HEALTH